🇯🇵 日本語 🇺🇸 English
3,791 companies 2,399 AI summaries 1,857 risk analyses 1,326 growth scores Register free — watchlist & alerts →
EDINET 4918 Neutral Risk Analyzed 📈 Growth 2/10

IVY COSMETICS CORPORATION

Annual Securities Report - 51st Term(2025/04/01 - 2026/03/31) ／ 2026-06-23 11:13

Covers EDINET statutory filings (TDNET timely disclosures / earnings flashes are not included).

EarningsDividend UpNew ProductNew MarketR&D
AI Summary 2026-06-23 11:15

FY2025 revenue declined 9.8% to ¥2.64B, operating profit fell 53.8% to ¥195M due to weak new product sales and sluggish distributor expansion. Net income rose 282.5% to ¥165M due to lower extraordinary losses. Equity ratio improved to 72.4%, enabling dividend resumption after 8 years.

KEY POINTS
  • Revenue down 9.8%, operating profit down 53.8%, with Q3-Q4 volatility revealing high operating leverage—core weakness in sales organization expansion despite 238 distributors
  • Equity ratio reaches 72.4% (target 60%+), net profit rebounds to ¥165M, 8-year dividend resumption planned to enhance shareholder returns
  • Distributor inventory normalized and field sales recovery signs emerge, but young customer/salesperson acquisition and DX transformation remain critical growth challenges in shrinking visit-sales market
📊 Revenue
Revenue -9.8% (¥2.93B → ¥2.64B)
💰 Operating profit
OP -53.8% (¥423M → ¥195M)
🔮 Outlook
FY2026 outlook: Revenue -0.1%, OP +2.4%, Net profit -14.9%. Focus on ¥9.2B revenue target and KPI recovery (inventory turnover 6mo, OPM 15%, equity ratio 60%).
📈 Growth outlook 📈 Growth 2/10
Cosmetics market barely growing (+1.2% YoY). Visit-sales channel faces structural decline due to lifestyle changes, intensifying competition, and young customer acquisition challenges. Company plans 5-year system overhaul but execution risk remains high.
Growth drivers
  • New product launches (peeling lotion, moisture sheet, Chulie premium set) driving customer satisfaction
  • International expansion (continued Taiwan export, new market entry planned)
  • Patent licensing for pharmaceutical/cosmetic applications (TGF-β inhibitor, etc.) as new revenue stream
  • Sales organization training reinforcement targeting 100,000 loyal users
Risk and growth scores and tags are AI-generated estimates from analyzing the disclosure. They are not guarantees of fact, nor investment advice or recommendations. Make investment decisions at your own discretion.
⚠️ Extracted Risk Factors
CategoryDescriptionScoreNew
Market Risk Visit-sales cosmetics market shrinking due to lifestyle changes and customer loss. Intensifying inter-company competition and cross-channel expansion pressuring margins. 7/10
Supply Chain Risk Middle East conflict and Hormuz Strait blockade threaten crude oil/naphtha supply routes. Global raw material suppliers face disruption risks impacting production. 7/10
Earnings Deterioration Risk High operating leverage to revenue—sharp sales decline causes disproportionate profit contraction. ¥9.2B target miss would severely impact earnings. 7/10
Customer Concentration Risk Wholesale to 238 distributors—company sales highly sensitive to distributor inventory policy. Overstocking risk remains despite recent normalization. 6/10
Regulatory Risk Strengthened visit-sales regulation under Special Trade Act could disrupt sales model. Pharmaceutical Affairs Law revisions may prohibit existing ingredients. 5/10
Credit Risk Distributor financial deterioration and zero-interest loan repayment squeeze raising default risk. Hidden deterioration in distributor finances possible. 5/10
Pandemic Risk Future pandemic could restrict face-to-face counseling and training, limiting salesperson and customer acquisition activities. 4/10
Foreign Exchange Risk International expansion exposure to FX volatility; export revenues may fall short of initial investment. 4/10
7/10 Market Risk
Visit-sales cosmetics market shrinking due to lifestyle changes and customer loss. Intensifying inter-company competition and cross-channel expansion pressuring margins.
7/10 Supply Chain Risk
Middle East conflict and Hormuz Strait blockade threaten crude oil/naphtha supply routes. Global raw material suppliers face disruption risks impacting production.
7/10 Earnings Deterioration Risk
High operating leverage to revenue—sharp sales decline causes disproportionate profit contraction. ¥9.2B target miss would severely impact earnings.
6/10 Customer Concentration Risk
Wholesale to 238 distributors—company sales highly sensitive to distributor inventory policy. Overstocking risk remains despite recent normalization.
5/10 Regulatory Risk
Strengthened visit-sales regulation under Special Trade Act could disrupt sales model. Pharmaceutical Affairs Law revisions may prohibit existing ingredients.
5/10 Credit Risk
Distributor financial deterioration and zero-interest loan repayment squeeze raising default risk. Hidden deterioration in distributor finances possible.
4/10 Pandemic Risk
Future pandemic could restrict face-to-face counseling and training, limiting salesperson and customer acquisition activities.
4/10 Foreign Exchange Risk
International expansion exposure to FX volatility; export revenues may fall short of initial investment.
X LinkedIn Threads Bluesky Facebook
Track Japanese disclosures with JSIGNAL

AI summaries, risk & growth analysis, watchlist alerts and a screener for every Japanese listed company.

Start free — 30-day trial Login